NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 01:30PM ET
1.89
Dollar change
+0.04
Percentage change
2.16
%
Index- P/E- EPS (ttm)-1.64 Insider Own38.78% Shs Outstand74.34M Perf Week14.55%
Market Cap140.51M Forward P/E- EPS next Y-0.49 Insider Trans0.00% Shs Float45.51M Perf Month-6.90%
Enterprise Value47.40M PEG- EPS next Q-0.09 Inst Own54.55% Short Float3.48% Perf Quarter-13.30%
Income-36.55M P/S- EPS this Y63.22% Inst Trans13.78% Short Ratio6.26 Perf Half Y-41.67%
Sales0.00M P/B1.64 EPS next Y-14.84% ROA-69.39% Short Interest1.59M Perf YTD-41.85%
Book/sh1.15 P/C1.51 EPS next 5Y27.25% ROE-79.02% 52W High4.20 -55.00% Perf Year52.42%
Cash/sh1.25 P/FCF- EPS past 3/5Y38.01% 18.99% ROIC-42.63% 52W Low1.12 68.75% Perf 3Y-60.63%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility11.44% 7.55% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM51.51% Oper. Margin- ATR (14)0.15 Perf 10Y-
Dividend Ex-Date- Quick Ratio11.01 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)51.83 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio11.01 EPS Q/Q79.16% SMA203.43% Beta0.93 Target Price8.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-3.80% Rel Volume0.32 Prev Close1.85
Employees16 LT Debt/Eq0.00 EarningsMay 14 AMC SMA200-16.07% Avg Volume253.24K Price1.89
IPODec 23, 2020 Option/ShortNo / Yes EPS/Sales Surpr.-50.00% - Trades Volume81,965 Change2.16%
Date Action Analyst Rating Change Price Target Change
Feb-12-25Downgrade H.C. Wainwright Buy → Neutral
May-14-25 04:05PM
May-02-25 05:07AM
Apr-14-25 08:00AM
Mar-27-25 04:01PM
Mar-05-25 09:55AM
08:00AM Loading…
Feb-24-25 08:00AM
Feb-18-25 08:00AM
Nov-14-24 08:37AM
Oct-23-24 06:31AM
Oct-22-24 09:07PM
Oct-21-24 09:05AM
Oct-18-24 01:01AM
Oct-11-24 05:57PM
01:02PM
Oct-10-24 08:59AM
09:18AM Loading…
Oct-09-24 09:18AM
Aug-14-24 04:25PM
Aug-07-24 08:00AM
Jun-17-24 08:05AM
Jun-05-24 08:05AM
May-20-24 08:01AM
May-19-24 08:09AM
May-16-24 06:52AM
May-15-24 08:00PM
08:45AM
May-09-24 08:00AM
Apr-18-24 04:30PM
Apr-03-24 08:05AM
Apr-02-24 10:25AM
Mar-28-24 09:06PM
10:53PM Loading…
Mar-27-24 10:53PM
04:15PM
Mar-07-24 08:30AM
Feb-28-24 04:05PM
Feb-15-24 09:55AM
Feb-07-24 07:55AM
Jan-29-24 09:05AM
Jan-22-24 12:00PM
Jan-16-24 04:05PM
Dec-19-23 08:30AM
Dec-04-23 08:35AM
Nov-14-23 04:30PM
Nov-07-23 09:28AM
08:00AM
Oct-16-23 07:00AM
Oct-04-23 08:30AM
Sep-20-23 08:30AM
Aug-24-23 08:30AM
Aug-22-23 08:05AM
Aug-21-23 08:30AM
Aug-17-23 08:30AM
Aug-15-23 11:47PM
Aug-14-23 04:20PM
Aug-07-23 08:05AM
Jul-17-23 04:05PM
Jun-29-23 09:29AM
Jun-22-23 08:05AM
Jun-21-23 08:05AM
May-30-23 08:05AM
May-24-23 12:04PM
May-17-23 06:11AM
May-16-23 07:45AM
May-15-23 08:30AM
May-09-23 07:15AM
May-08-23 08:05AM
May-04-23 08:05AM
May-02-23 03:30PM
Apr-26-23 08:00AM
Apr-24-23 09:00AM
Apr-21-23 08:30AM
Apr-07-23 10:25PM
Mar-31-23 08:22AM
Mar-23-23 05:15PM
Mar-21-23 08:00AM
Mar-16-23 08:30AM
Mar-15-23 08:35AM
Mar-08-23 08:30AM
Feb-15-23 04:05PM
Feb-08-23 01:00PM
Jan-27-23 04:05PM
Jan-25-23 01:00PM
08:35AM
08:05AM
Dec-12-22 04:05PM
Dec-07-22 04:05PM
Nov-22-22 08:00AM
Nov-14-22 05:45PM
Nov-10-22 05:00AM
Nov-08-22 08:00AM
Nov-07-22 08:00AM
Oct-12-22 08:00AM
Sep-21-22 04:05PM
Sep-15-22 08:00AM
Sep-13-22 12:15PM
Sep-08-22 08:30AM
Sep-01-22 04:05PM
Aug-26-22 08:00AM
Aug-23-22 08:00AM
Aug-12-22 04:55PM
Aug-08-22 08:30AM
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bellini RobertoDirectorOct 21 '24Buy1.371,460,0002,000,2001,460,000Oct 23 07:53 PM
Kush ArvindDirectorOct 21 '24Buy1.37145,000198,650145,000Oct 23 07:49 PM
Munshi AmitDirectorOct 21 '24Buy1.37365,000500,050365,000Oct 23 07:43 PM